Back to Authors

Galasko, Douglas

https://orcid.org/0000-0001-6195-3241

A5072592799 | I36258959

Mayo Clinic

University of California San Diego

Citations 49

S3‐03‐04: Prevalence study in Shanghai

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2009.05.659

P1‐207: Assessing quality of life by EQ‐5D among Chinese elderly with cognitive function impairment: Findings from SCOBHI pilot

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2009.04.214

P2‐067: Shanghai community brain health initiative (scobhi) pilot study: apoe findings

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2009.04.377

P2‐064: Shanghai community brain health initiative (scobhi) pilot study: methods and participation rates

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2009.04.374

P3‐107: Shanghai community brain health initiative: Pilot study. Neuropsychological results

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_12 | Pages: No page available

10.1016/j.jalz.2009.04.1082

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine | April 23, 2009 | Volume: 46 | Issue: 3 | Pages: 235-240

10.1258/acb.2009.008232 | PMID 19342441

Background Different cerebrospinal fluid (CSF) amyloid-beta 1–42 (A β 1–42 ), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres. Methods Three CSF-pool samples were distributed to 13 laboratories in 2004 and the same samples were again distributed to 18 laboratories in 2008. In 2004 six laboratories measured A β 1–42 , Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex. Results In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for A β 1–42 , Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotest ® ( N = 13) for A β 1–42 , lower interCV were calculated (22%). The centres that participated in both years ( N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008. Conclusions The highest variability was found for A β 1–42 . The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.
Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia

Journal of Clinical and Experimental Neuropsychology | February 17, 2009 | Volume: 31 | Issue: 7 | Pages: 823-834

10.1080/13803390802572401 | PMID 19221922

Rate of progression differs in frontotemporal dementia and Alzheimer disease

Neurology | July 12, 2006 | Volume: 65 | Issue: 3 | Pages: 397-403

10.1212/01.wnl.0000171343.43314.6e | PMID 16087904

[O2‐01‐01]: Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard‐ratio analysis

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.326